pubmed-article:17606455 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C1333568 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0023487 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0010802 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0052416 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0175668 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
pubmed-article:17606455 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
pubmed-article:17606455 | pubmed:issue | 7 | lld:pubmed |
pubmed-article:17606455 | pubmed:dateCreated | 2007-7-3 | lld:pubmed |
pubmed-article:17606455 | pubmed:abstractText | Ninety-eight newly diagnosed cases of PML-RARalpha positive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARalpha isoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome. | lld:pubmed |
pubmed-article:17606455 | pubmed:language | eng | lld:pubmed |
pubmed-article:17606455 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17606455 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17606455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17606455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17606455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17606455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17606455 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17606455 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17606455 | pubmed:month | Jul | lld:pubmed |
pubmed-article:17606455 | pubmed:issn | 1592-8721 | lld:pubmed |
pubmed-article:17606455 | pubmed:author | pubmed-author:GeorgeBijuB | lld:pubmed |
pubmed-article:17606455 | pubmed:author | pubmed-author:SrivastavaAlo... | lld:pubmed |
pubmed-article:17606455 | pubmed:author | pubmed-author:MathewsVikram... | lld:pubmed |
pubmed-article:17606455 | pubmed:author | pubmed-author:ChandyMammenM | lld:pubmed |
pubmed-article:17606455 | pubmed:author | pubmed-author:ThomasMariaM | lld:pubmed |
pubmed-article:17606455 | pubmed:author | pubmed-author:SrivastavaViv... | lld:pubmed |
pubmed-article:17606455 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:17606455 | pubmed:volume | 92 | lld:pubmed |
pubmed-article:17606455 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17606455 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17606455 | pubmed:pagination | 994-5 | lld:pubmed |
pubmed-article:17606455 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:meshHeading | pubmed-meshheading:17606455... | lld:pubmed |
pubmed-article:17606455 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17606455 | pubmed:articleTitle | Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. | lld:pubmed |
pubmed-article:17606455 | pubmed:affiliation | Department of Haematology, Christian Medical College, Vellore, 632004 India. vikram@cmcvellore.ac.in | lld:pubmed |
pubmed-article:17606455 | pubmed:publicationType | Journal Article | lld:pubmed |
entrez-gene:2322 | entrezgene:pubmed | pubmed-article:17606455 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17606455 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17606455 | lld:entrezgene |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17606455 | lld:pubmed |